Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2015

View Archived Issues

Shionogi reflects on key events of fourth quarter of fiscal 2014

Protease-activated fluorescent agent images residual disease during surgery

Amarantus BioScience reports data on multiple sclerosis diagnostic

Dana-Farber/Boston Children's joins phase I pediatric immunotherapy trial for ALL

Novel ERK inhibitor active in MAPK pathway-dependent cancers

PARP-1/2 inhibition enhances chemotherapeutics' antitumor effect

Antiviral fusion inhibitor presatovir, a promising candidate to treat RSV infection

Artax Biopharma patents TCR/NCK interaction inhibitors

Pain Therapeutics releases topline results from human abuse potential study of Remoxy

Bayer dislcoses factor XIa and kallikrein B inhibitors

Bristol-Myers Squibb reports 11beta-HSD1 inhibitors

Insmed introduces new prostacyclin analogues

PDE2A inhibitors reported in recent Takeda patent

FDA accepts IND for Aspyrian's RM-1929 for head and neck cancer

Inovio starts phase I trial of Ebola virus DNA vaccine

Pfizer invests in AM-Pharma and obtains acquisition option

Vivione Biosciences establishes research collaboration to develop bacterial infection diagnostics

Sucampo licenses Amitiza rights in China to Harbin Gloria

Moderna Therapeutics launches Elpidera to discover mRNA therapies for rare diseases

AstraZeneca and Abbott to develop tralokinumab companion diagnostic for asthma

Santen divests its RA business to focus on ophthalmology

Researchers report phase II results of VXM-01 in pancreatic cancer patients

Baxter to acquire Oncaspar portfolio from Sigma-Tau

Immunomic Therapeutics receives grant to develop peanut allergy vaccine

Bavarian Nordic reports results of pivotal trials of liquid-frozen and freeze-dried Imvamune

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...